About Us

Catherine Sabatos-Peyton, Ph.D., is Larkspur Bioscience’s Chief Executive Officer. Most recently Executive Director, Head of Immune Modulation at the Novartis Institutes for BioMedical Research (NIBR), Catherine spent 7 years building the team focused on biologics and small molecule drug development programs. Previously, while at the biotech CoStim, Catherine led the discovery of the first-in-class anti-TIM-3 antibody, sabatolimab, and then oversaw its advancement to Phase 2/3 studies in acute myeloid leukemia and myelodysplastic syndrome at NIBR. After embarking on autoimmunity research during a Fulbright Fellowship at Oxford, Catherine received her Ph.D. in Immunology from Harvard University.

Krista Goodman, Ph.D., is Chief Scientific Officer. She secured both a MS and Ph.D. in Chemistry at Harvard University studying synthetic organic chemistry in the labs of Dave Evans while working on natural products total synthesis. Prior to Larkspur, Krista spent 20 years at GSK, most recently as Global Head and Senior Director of Flexible Medicinal Chemistry, Medicine Design. During her tenure at GSK, Krista served in global leadership roles where her groups were accountable for delivering drug leads and candidates across GSK’s entire portfolio, including oncology and immunology as well as infectious diseases and other areas of focus. She was also accountable for GSK’s chemistry outsourcing strategy and global lab operations. Additionally, while leading a newly formed early discover chemistry group at GSK, Krista and her team prosecuted over fifty different targets across the full spectrum of target classes, therapeutic areas, and small molecule modalities. She also has extensive experience with enzymes and kinases.

Emily Corse, Ph.D., is EVP, Biology & Translation. Emily joined Larkspur from Boehringer Ingelheim where she was recruited to build from scratch cancer immunology research in the US, focused on mechanisms that relieve T cell suppression in the tumor microenvironment. Previously, Emily was a Senior Principal Scientist for pRED Cancer Immunotherapy at Roche, where she supported their increased efforts in antibody therapies for cancer immunology. Emily trained in molecular virology and cell biology, then became interested in the elegance of T cell receptor / peptide MHC interactions through an immunology course and pursued that topic as a postdoc with Jim Allison (founder of T cell checkpoint inhibition for oncology and Nobel laureate) at MD Anderson. Before leaving Texas, Emily was an assistant professor of immunology at University of Texas / MD Anderson. She received her Ph.D. in cell biology from Johns Hopkins University School of Medicine.